Literature DB >> 10603391

Development of a DeltaglnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae.

E T Ryan1, T I Crean, S K Kochi, M John, A A Luciano, K P Killeen, K E Klose, S B Calderwood.   

Abstract

We have previously shown that more prominent immune responses are induced to antigens expressed from multicopy plasmids in live attenuated vaccine vector strains of Vibrio cholerae than to antigens expressed from single-copy genes on the V. cholerae chromosome. Here, we report the construction of a DeltaglnA derivative of V. cholerae vaccine strain Peru2. This mutant strain, Peru2DeltaglnA, is unable to grow on medium that does not contain glutamine; this growth deficiency is complemented by pKEK71-NotI, a plasmid containing a complete copy of the Salmonella typhimurium glnA gene, or by pTIC5, a derivative of pKEK71-NotI containing a 1. 8-kbp fragment that directs expression of CtxB with a 12-amino-acid epitope of the serine-rich Entamoeba histolytica protein fused to the amino terminus. Strain Peru2DeltaglnA(pTIC5) produced 10-fold more SREHP-12-CtxB in supernatants than did ETR3, a Peru2-derivative strain containing the same fragment inserted on the chromosome. To assess immune responses to antigens expressed by this balanced lethal system in vivo, we inoculated germfree mice on days 0, 14, 28, and 42 with Peru2DeltaglnA, Peru2DeltaglnA(pKEK71-NotI), Peru2(pTIC5), Peru2DeltaglnA(pTIC5), or ETR3. All V. cholerae strains were recoverable from stool for 8 to 12 days after primary inoculation, including Peru2DeltaglnA; strains containing plasmids continued to harbor pKEK71-NotI or pTIC5 for 8 to 10 days after primary inoculation. Animals were sacrificed on day 56, and serum, stool and biliary samples were analyzed for immune responses. Vibriocidal antibody responses, reflective of in vivo colonization, were equivalent in all groups of animals. However, specific anti-CtxB immune responses in serum (P </= 0.05) and bile (P </= 0. 001) were significantly higher in animals that received Peru2DeltaglnA(pTIC5) than in those that received ETR3, confirming the advantage of higher-level antigen expression in vivo. The development of this balanced lethal system thus permits construction and maintenance of vaccine and vector strains of V. cholerae that express high levels of immunogenic antigens from plasmid vectors without the need for antibiotic selection pressure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10603391      PMCID: PMC97124          DOI: 10.1128/IAI.68.1.221-226.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector.

Authors:  M S Donnenberg; J B Kaper
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

2.  Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I.

Authors:  C J Hovde; S B Calderwood; J J Mekalanos; R J Collier
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

3.  A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR.

Authors:  V L Miller; J J Mekalanos
Journal:  J Bacteriol       Date:  1988-06       Impact factor: 3.490

4.  Allelic exchange in Escherichia coli using the Bacillus subtilis sacB gene and a temperature-sensitive pSC101 replicon.

Authors:  I C Blomfield; V Vaughn; R F Rest; B I Eisenstein
Journal:  Mol Microbiol       Date:  1991-06       Impact factor: 3.501

5.  Identification of an iron-regulated virulence determinant in Vibrio cholerae, using TnphoA mutagenesis.

Authors:  M B Goldberg; V J DiRita; S B Calderwood
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

6.  Use of the Vibrio cholerae irgA gene as a locus for insertion and expression of heterologous antigens in cholera vaccine strains.

Authors:  J R Butterton; S A Boyko; S B Calderwood
Journal:  Vaccine       Date:  1993-10       Impact factor: 3.641

Review 7.  Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype.

Authors:  M K Waldor; J J Mekalanos
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

8.  Isogenic P-fimbrial deletion mutants of pyelonephritogenic Escherichia coli: the role of alpha Gal(1-4) beta Gal binding in virulence of a wild-type strain.

Authors:  H L Mobley; K G Jarvis; J P Elwood; D I Whittle; C V Lockatell; R G Russell; D E Johnson; M S Donnenberg; J W Warren
Journal:  Mol Microbiol       Date:  1993-10       Impact factor: 3.501

9.  Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory.

Authors:  M Quiding; I Nordström; A Kilander; G Andersson; L A Hanson; J Holmgren; C Czerkinsky
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

10.  CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor.

Authors:  G D Pearson; A Woods; S L Chiang; J J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

View more
  14 in total

Review 1.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

2.  Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and vector strains.

Authors:  T I Crean; M John; S B Calderwood; E T Ryan
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Prolonged colonization of mice by Vibrio cholerae El Tor O1 depends on accessory toxins.

Authors:  Verena Olivier; Nita H Salzman; Karla J Fullner Satchell
Journal:  Infect Immun       Date:  2007-08-13       Impact factor: 3.441

Review 4.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

Review 5.  Antibiotic-free selection in biotherapeutics: now and forever.

Authors:  Charlotte Mignon; Régis Sodoyer; Bettina Werle
Journal:  Pathogens       Date:  2015-04-03

Review 6.  Salmonella as a vaccine delivery vehicle.

Authors:  Kenneth L Roland; Karen E Brenneman
Journal:  Expert Rev Vaccines       Date:  2013-09       Impact factor: 5.217

7.  Novel antibiotic-free plasmid selection system based on complementation of host auxotrophy in the NAD de novo synthesis pathway.

Authors:  Wei-Ren Dong; Li-Xin Xiang; Jian-Zhong Shao
Journal:  Appl Environ Microbiol       Date:  2010-01-29       Impact factor: 4.792

8.  Use of mchI encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors.

Authors:  Chee-Mun Fang; Jin Yuan Wang; Magaly Chinchilla; Myron M Levine; William C Blackwelder; James E Galen
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

9.  Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108.

Authors:  Weili Liang; Shixia Wang; Fenggang Yu; Lijuan Zhang; Guoming Qi; Yanqing Liu; Shouyi Gao; Biao Kan
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

Review 10.  Exploiting cholera vaccines as a versatile antigen delivery platform.

Authors:  Anisia J Silva; Francis O Eko; Jorge A Benitez
Journal:  Biotechnol Lett       Date:  2007-11-16       Impact factor: 2.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.